Development of novel agents for the treatment of early estrogen receptor positive breast cancer

被引：11

作者：

Elliott, Mitchell J.

Cescon, David W.

机构：

[1] Univ Hlth Network, Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada

[2] Univ Toronto, Toronto, ON, Canada

来源：

BREAST | 2022年 / 62卷

关键词：

Breast cancer; Adjuvant therapy; Endocrine therapy; Targeted agents; Estrogen receptor; mTOR; PI3K; SERD; AKT; Early breast cancer; PARP inhibitor; CIRCULATING TUMOR DNA; FIRST-LINE THERAPY; POSTMENOPAUSAL WOMEN; PHASE-III; ENDOCRINE THERAPY; DOUBLE-BLIND; NEOADJUVANT TREATMENT; AROMATASE INHIBITOR; PIK3CA MUTATIONS; PLUS LETROZOLE;

D O I：

10.1016/j.breast.2021.11.007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Estrogen receptor (ER+) breast cancer is the most frequently diagnosed breast cancer subtype. Currently, adjuvant treatment for early stage disease consists of endocrine therapy, with or without chemotherapy and bone-targeted therapy, delivered in a risk-adapted manner. Despite this multimodal approach, a significant proportion of high risk patients will develop incurable distant recurrences. There is an ongoing need to develop new treatment strategies that address the biologic causes of treatment failure and to identify the individual patients who can benefit from such interventions. Here we review the clinical investigation of targeted and novel therapies, including inhibitors of the PI3K-AKT-mTOR pathway, oral selective estrogen receptor degraders (SERDs), and PARP-inhibitors for the treatment of early ER+ breast cancer. Furthermore, we highlight opportunities in biomarker development to help guide the delivery of escalated adjuvant strategies. (C) 2021 Published by Elsevier Ltd.

引用

页码：S34 / S42

页数：9

共 86 条

[1] Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study [J].

Alba, E. ;

Calvo, L. ;

Albanell, J. ;

De la Haba, J. R. ;

Arcusa Lanza, A. ;

Chacon, J. I. ;

Sanchez-Rovira, P. ;

Plazaola, A. ;

Lopez Garcia-Asenjo, J. A. ;

Bermejo, B. ;

Carrasco, E. ;

Lluch, A. .

ANNALS OF ONCOLOGY, 2012, 23 (12) :3069-3074

[2] Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2enegative advanced breast cancer: final overall survival results from SOLAR-1 [J].

Andre, F. ;

Ciruelos, E. M. ;

Juric, D. ;

Loibl, S. ;

Campone, M. ;

Mayer, I. A. ;

Rubovszky, G. ;

Yamashita, T. ;

Kaufman, B. ;

Lu, Y-S ;

Inoue, K. ;

Papai, Z. ;

Takahashi, M. ;

Ghaznawi, F. ;

Mills, D. ;

Kaper, M. ;

Miller, M. ;

Conte, P. F. ;

Iwata, H. ;

Rugo, H. S. .

ANNALS OF ONCOLOGY, 2021, 32 (02) :208-217

[3] Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer [J].

Andre, Fabrice ;

Ciruelos, Eva ;

Rubovszky, Gabor ;

Campone, Mario ;

Loibl, Sibylle ;

Rugo, Hope S. ;

Iwata, Hiroji ;

Conte, Pierfranco ;

Mayer, Ingrid A. ;

Kaufman, Bella ;

Yamashita, Toshinari ;

Lu, Yen-Shen ;

Inoue, Kenichi ;

Takahashi, Masato ;

Papai, Zsuzsanna ;

Longin, Anne-Sophie ;

Mills, David ;

Wilke, Celine ;

Hirawat, Samit ;

Juric, Dejan .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (20) :1929-1940

[4]

[Anonymous], 2021, STUD EV EFF SAF ADJ

[5] Efficacy of everolimus in patientswith HRD/HER2-high risk early stage breast cancer [J].

Bachelot, T. ;

Dalenc, F. ;

Chabaud, S. ;

Cottu, P. ;

Allouache, D. ;

Brain, E. ;

Jacquin, J-P. ;

Grenier, J. ;

Bouvet, L. Venat ;

Brunt, M. ;

Campone, M. ;

Del Piano, F. ;

Debled, M. ;

Bessard, A-C. Hardy ;

Giacchetti, S. ;

Bliss, J. ;

Canon, J-L. ;

Lemonnier, J. ;

Cameron, D. ;

Andre, F. .

ANNALS OF ONCOLOGY, 2021, 32 (04) :574-575

[6]

Bardia A, 2021, J CLIN ONCOL

[7] Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer [J].

Baselga, Jose ;

Campone, Mario ;

Piccart, Martine ;

Burris, Howard A., III ;

Rugo, Hope S. ;

Sahmoud, Tarek ;

Noguchi, Shinzaburo ;

Gnant, Michael ;

Pritchard, Kathleen I. ;

Lebrun, Fabienne ;

Beck, J. Thaddeus ;

Ito, Yoshinori ;

Yardley, Denise ;

Deleu, Ines ;

Perez, Alejandra ;

Bachelot, Thomas ;

Vittori, Luc ;

Xu, Zhiying ;

Mukhopadhyay, Pabak ;

Lebwohl, David ;

Hortobagyi, Gabriel N. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (06) :520-529

[8] Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor-Positive Breast Cancer [J].

Baselga, Jose ;

Semiglazov, Vladimir ;

van Dam, Peter ;

Manikhas, Alexey ;

Bellet, Meritxell ;

Mayordomo, Jose ;

Campone, Mario ;

Kubista, Ernst ;

Greil, Richard ;

Bianchi, Giulia ;

Steinseifer, Jutta ;

Molloy, Betty ;

Tokaji, Erika ;

Gardner, Humphrey ;

Phillips, Penny ;

Stumm, Michael ;

Lane, Heidi A. ;

Dixon, J. Michael ;

Jonat, Walter ;

Rugo, Hope S. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (16) :2630-2637

[9] Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women:: Results of the tamoxifen or arimidex randomized group efficacy and tolerability study [J].

Bonneterre, J ;

Thürlimann, B ;

Robertson, JFR ;

Krzakowski, M ;

Mauriac, L ;

Koralewski, P ;

Vergote, I ;

Webster, A ;

Steinberg, M ;

von Euler, M .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (22) :3748-3757

[10] Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer [J].

Burstein, Harold J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (26) :2557-2570

← 1 2 3 4 5 6 7 8 9 →